logo
  • Home
  • Solution
  • Impact
  • Science
    • Publications
  • About
    • Team and Board
  • News and Events
    • All News
    • All Events
    • All Press Releases
  • Contact

Funding secured for the next step of BioC clinical plan

15 July, 2022
|In News
|By Helene Hartman

The interest was very high and a new issue of 14M SEK was oversubscribed. The money will be used for the clinical phase Ib study on patient with complex wounds and for preparation of the clinical trial phase II.

Recent Posts

  • Xinnate granted patent in Japan for TCP-25 formulation. The patent further strengthens the global intellectual property protection of the TCP-25 gel.
  • Xinnate AB har fått patent godkänt i Japan avseende formulering av TCP-25. Patentet är innebär ett ytterligare stärkt globalt immateriellt skydd för TCP-25 gelen.
  • Xinnate announces that recruitment has started and the first patient has been included in the STEP study with TCP-25
  • Xinnate meddelar att rekryteringen har startat och första patienten har blivit inkluderad i STEP-studien med TCP-25
  • First Scientific Publication Reporting Clinical Trial Results for Xinnate’s Proprietary Drug Candidate TCP-25

Archives

  • February 2026
  • January 2026
  • December 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • January 2025
  • December 2024
  • September 2024
  • May 2024
  • March 2024
  • February 2024
  • March 2023
  • October 2022
  • September 2022
  • July 2022
  • March 2022
  • August 2021
  • October 2020
  • January 2020
  • Prev
  • Next
© 2026 Xinnate. All rights reserved